Early Cancer Screening with Pteridines as Biomarkers

Abstract

Early detection and treatment of cancers continue to be the best line of defense to prevent fatalities as a result of developing cancer. Several tests have been developed, such as mammograms for breast cancer and colonoscopies for colon cancer, but most of these tests are invasive, uncomfortable and are not always able to detect cancer earlier enough to provide a winning scenario for patients. Some cancers are still very difficult to diagnose in the early stage, such as ovarian cancer, colorectal cancer, and some liver cancers. In our study, we have developed a P-scan instrument to successfully identify and quantify six pteridines in urine samples. The data demonstrated a great correlation between pteridine levels and cancer development. The detailed experimental conditions will be presented at the life science summit. After analysis of over 60 urine samples from cancer patients, we also discovered that two chemical components exist only in the urine of cancer patients but are not present in individuals who do not have cancers.